These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18625257)

  • 1. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
    Lopez S; Turle-Lorenzo N; Johnston TH; Brotchie JM; Schann S; Neuville P; Amalric M
    Neuropharmacology; 2008 Sep; 55(4):483-90. PubMed ID: 18625257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
    Konieczny J; Wardas J; Kuter K; Pilc A; Ossowska K
    Neuroscience; 2007 Mar; 145(2):611-20. PubMed ID: 17224239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity.
    Lopez S; Jouve L; Turle-Lorenzo N; Kerkerian-Legoff L; Salin P; Amalric M
    Neurobiol Dis; 2012 Apr; 46(1):69-77. PubMed ID: 22245662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
    Jones CK; Bubser M; Thompson AD; Dickerson JW; Turle-Lorenzo N; Amalric M; Blobaum AL; Bridges TM; Morrison RD; Jadhav S; Engers DW; Italiano K; Bode J; Daniels JS; Lindsley CW; Hopkins CR; Conn PJ; Niswender CM
    J Pharmacol Exp Ther; 2012 Feb; 340(2):404-21. PubMed ID: 22088953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
    Fuzzati-Armentero MT; Cerri S; Levandis G; Ambrosi G; Montepeloso E; Antoninetti G; Blandini F; Baqi Y; Müller CE; Volpini R; Costa G; Simola N; Pinna A
    J Neurochem; 2015 Aug; 134(4):740-7. PubMed ID: 25962878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
    Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
    Johnson KA; Jones CK; Tantawy MN; Bubser M; Marvanova M; Ansari MS; Baldwin RM; Conn PJ; Niswender CM
    Neuropharmacology; 2013 Mar; 66():187-95. PubMed ID: 22546615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
    Greco B; Lopez S; van der Putten H; Flor PJ; Amalric M
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1064-71. PubMed ID: 19940105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined antagonism of glutamate mGlu5 and adenosine A2A receptors interact to regulate alcohol-seeking in rats.
    Adams CL; Cowen MS; Short JL; Lawrence AJ
    Int J Neuropsychopharmacol; 2008 Mar; 11(2):229-41. PubMed ID: 17517168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
    Alam M; Danysz W; Schmidt WJ; Dekundy A
    Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents.
    Pałucha-Poniewiera A; Kłodzińska A; Stachowicz K; Tokarski K; Hess G; Schann S; Frauli M; Neuville P; Pilc A
    Neuropharmacology; 2008 Sep; 55(4):517-24. PubMed ID: 18619473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
    Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
    Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
    Coccurello R; Breysse N; Amalric M
    Neuropsychopharmacology; 2004 Aug; 29(8):1451-61. PubMed ID: 15039773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.
    Lopez S; Turle-Lorenzo N; Acher F; De Leonibus E; Mele A; Amalric M
    J Neurosci; 2007 Jun; 27(25):6701-11. PubMed ID: 17581957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
    Breysse N; Baunez C; Spooren W; Gasparini F; Amalric M
    J Neurosci; 2002 Jul; 22(13):5669-78. PubMed ID: 12097518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid.
    Chapman AG; Talebi A; Yip PK; Meldrum BS
    Eur J Pharmacol; 2001 Jul; 424(2):107-13. PubMed ID: 11476756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
    Turle-Lorenzo N; Breysse N; Baunez C; Amalric M
    Psychopharmacology (Berl); 2005 Apr; 179(1):117-27. PubMed ID: 15726332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
    Konieczny J; Lenda T
    Pharmacol Rep; 2013; 65(5):1194-203. PubMed ID: 24399715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice.
    Pałucha-Poniewiera A; Novák K; Pilc A
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1454-7. PubMed ID: 19660510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.